Stock Groups

CDC advisers to review data on wider use of Pfizer-BioNTech COVID-19 vaccine -Breaking


© Reuters. FILE PHOTO – A panoramic view of Atlanta’s U.S. Centers for Disease Control and Prevention Headquarters (CDC), September 30, 2014. REUTERS/Tami Chappell

(Reuters) – Friday’s meeting of the advisory group at U.S. Centers for Disease Control and Prevention will discuss expanding eligibility for booster dosages. Pfizer (NYSE:), and BioNTech partner’s COVID-19 vaccin, which is available to select populations.

Pfizer requested that the U.S. Food and Drug Administration (FDA), authorize the use of booster doses for all adults earlier this month. They presented data that the shots would be effective in preventing disease at any age.

This third dosage has been approved for people with immunocompromised, 65 years and older, those who have high risks of serious disease and are frequently exposed to the virus.

In August, U.S. President Joe Biden announced that he would roll out booster doses to all adult patients in September.

Based on recommendations by the Advisory Committee on Immunization Practices, the CDC establishes U.S. childhood and adult immunization programs.

Disclaimer: Fusion MediaThis website does not provide accurate and current data. CFDs are stocks, indexes or futures. The prices of Forex and CFDs are not supplied by exchanges. They are instead provided by market makers. As such, the prices might not reflect market values and could be incorrect. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this information. This includes data including charts and buy/sell signal signals. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.